Accueil › Leucémie aiguë myéloïde › Arkansas › Little Rock
Essais cliniques pour Leucémie aiguë myéloïde à Little Rock, AR
13 études pour Leucémie aiguë myéloïde recherchent des participants dans et autour de Little Rock (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Recrutement en coursPhase 2
- University of Arkansas for Medical Sciences, Little Rock
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Recrutement en coursÉtude observationnelleVolontaires sains bienvenus
- CARTI Cancer Center, Little Rock
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Recrutement en coursPhase 2
- University of Arkansas for Medical Sciences, Little Rock
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Recrutement en coursPhase 3
- University of Arkansas at Little Rock, Little Rock
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Recrutement en coursPhase 2
- University of Arkansas for Medical Sciences, Little Rock
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Recrutement en coursPhase 2
- University of Arkansas for Medical Sciences, Little Rock
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Recrutement en coursPhase 2
- University of Arkansas for Medical Sciences, Little Rock
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Recrutement en coursPhase 3
- Arkansas Children's Hospital, Little Rock
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
Recrutement en coursPhase 3
- Arkansas Children's Hospital, Little Rock
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Recrutement en coursPhase 1/2
- Arkansas Children's Hospital, Little Rock
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Recrutement en coursPhase 3
- Arkansas Children's Hospital, Little Rock
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Recrutement en coursÉtude observationnelle
- Arkansas Children's Hospital, Little Rock
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
Recrutement en coursPhase 1
- Arkansas Children's Hospital, Little Rock
Essais pour Leucémie aiguë myéloïde dans d'autres villes
- Houston, TX85 études
- New York City, NY51 études
- Boston, MA44 études
- Seattle, WA41 études
- Baldwin Park, CA40 études
- Columbus, OH35 études
- Philadelphia, PA34 études
- Durham, NC33 études
- Atlanta, GA31 études
- Tampa, FL29 études
- Chicago, IL26 études
- Portland, OR25 études
Autres études à Little Rock
- Schizophrénie19 études
- Cancer (tous types)14 études
- Trouble dépressif majeur14 études
- Cancer du poumon non à petites cellules13 études
- Obésité11 études
- Cancer de l'endomètre10 études
- Dépression10 études
- Diabète de type 210 études
- Cancer du poumon9 études
- Maladie cardiovasculaire9 études
- Cancer de la vessie9 études
- Insuffisance cardiaque9 études
Source : ClinicalTrials.gov, données récupérées le 6 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.